130 related articles for article (PubMed ID: 38442576)
1. PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells.
Xue X; Ye G; Zhang L; Zhu X; Liu Q; Rui G; Geng G; Lin Y; Chen X
Int Immunopharmacol; 2024 Mar; 130():111747. PubMed ID: 38442576
[TBL] [Abstract][Full Text] [Related]
2. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
[TBL] [Abstract][Full Text] [Related]
3. Short-chain fatty acids induced lung tumor cell death and increased peripheral blood CD4+ T cells in NSCLC and control patients ex vivo.
Thome CD; Tausche P; Hohenberger K; Yang Z; Krammer S; Trufa DI; Sirbu H; Schmidt J; Finotto S
Front Immunol; 2024; 15():1328263. PubMed ID: 38650948
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
[TBL] [Abstract][Full Text] [Related]
5. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
[TBL] [Abstract][Full Text] [Related]
6. Evidence of immunogenic cancer cell death induced by honey-processed Astragalus polysaccharides in vitro and in vivo.
Sha X; Xu X; Liao S; Chen H; Rui W
Exp Cell Res; 2022 Jan; 410(1):112948. PubMed ID: 34826423
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway.
Wang F; Mao Y; You Q; Hua D; Cai D
Int J Immunopathol Pharmacol; 2015 Sep; 28(3):362-73. PubMed ID: 26246196
[TBL] [Abstract][Full Text] [Related]
8. Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors.
Song D; Tang L; Wang L; Huang J; Zeng T; Fang H; Wang X
Cell Biol Toxicol; 2020 Feb; 36(1):51-64. PubMed ID: 31522336
[TBL] [Abstract][Full Text] [Related]
9. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
Dong C; Chen Y; Li H; Yang Y; Zhang H; Ke K; Shi XN; Liu X; Li L; Ma J; Kung HF; Chen C; Lin MC
Int J Biol Sci; 2019; 15(7):1523-1532. PubMed ID: 31337981
[No Abstract] [Full Text] [Related]
10. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer.
Zhu S; Ma AH; Zhu Z; Adib E; Rao T; Li N; Ni K; Chittepu VCSR; Prabhala R; Garisto Risco J; Kwiatkowski D; Mouw K; Sonpavde G; Cheng F; Pan CX
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725212
[TBL] [Abstract][Full Text] [Related]
12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
13. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
[TBL] [Abstract][Full Text] [Related]
15. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
19. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
20. An ER-Targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small-Cell Lung Cancer.
Wang L; Guan R; Xie L; Liao X; Xiong K; Rees TW; Chen Y; Ji L; Chao H
Angew Chem Int Ed Engl; 2021 Feb; 60(9):4657-4665. PubMed ID: 33217194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
